Kindred Biosciences ROA 2024

Kindred Biosciences Aktienanalyse

What does Kindred Biosciences do?

Kindred Biosciences Inc. is a biopharmaceutical company that was founded in 2012 by Richard Chin, an experienced pharmaceutical entrepreneur. The company's goal is to develop and bring to market innovative animal medicines for pets. The business model of Kindred Biosciences is based on the identification and development of novel, safe, and effective animal medicines for dogs, cats, and horses. The company utilizes state-of-the-art technologies and research methods to develop high-quality products that meet the needs of veterinarians and pet owners. The company currently has three main business segments: biologics, biopharmaceuticals, and small molecules. Each of these segments focuses on specific animal diseases and offers a unique range of products. The biologics segment of Kindred Biosciences develops innovative vaccines for dogs and cats that are highly effective and have improved tolerability. Kindred Biosciences' vaccines are specifically tailored to the needs of pets and can help prevent infections and diseases in dogs and cats. The biopharmaceuticals segment of Kindred Biosciences develops novel therapies for chronic diseases in dogs and cats, such as chronic pain, inflammation, and cancer. The company utilizes state-of-the-art technologies and research methods to develop effective and safe therapies that meet the needs of veterinarians and pet owners. The small molecules segment of Kindred Biosciences develops novel drugs for horses that are highly effective and have improved tolerability. Kindred Biosciences' drugs are specifically tailored to the needs of horses and can help treat various conditions such as arthritis or colic. The company has a broad range of products, currently consisting of over a dozen products that focus on different animal species, diseases, and needs. These include therapies for chronic pain, inhalation anesthetics, drugs for cancer and inflammation, as well as vaccines for various infections. Kindred Biosciences has achieved significant success in recent years. The company has conducted numerous clinical trials and brought several drugs and vaccines to market. In 2018, the company received approval from the Food and Drug Administration (FDA) for a groundbreaking therapy for chronic pain in dogs. The company also has a strong pipeline of products in development that could contribute to supporting the company's growth in the coming years. In summary, Kindred Biosciences is an innovative biopharmaceutical company focused on the development and commercialization of innovative animal medicines. The company has a broad range of products and is capable of developing high-quality products for a variety of animal species, diseases, and needs. With a strong pipeline and a successful track record, Kindred Biosciences is well-positioned to solidify its leading position in the industry and accelerate its growth in the coming years. Kindred Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Kindred Biosciences's Return on Assets (ROA)

Kindred Biosciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Kindred Biosciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Kindred Biosciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Kindred Biosciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Kindred Biosciences stock

What is the Return on Assets (ROA) of Kindred Biosciences this year?

The Return on Assets (ROA) of Kindred Biosciences is 0 undefined this year.

What was the ROA of Kindred Biosciences compared to the previous year?

The ROA of Kindred Biosciences has increased by 0% compared to the previous year.

What consequences do high ROA have for investors of Kindred Biosciences?

A high ROA is advantageous for investors of Kindred Biosciences, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Kindred Biosciences?

A low ROA can be unfavorable for investors of Kindred Biosciences as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Kindred Biosciences affect the company?

An increase in ROA of Kindred Biosciences can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Kindred Biosciences impact the company?

A reduction in the ROA of Kindred Biosciences can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Kindred Biosciences?

Some factors that can influence the ROA of Kindred Biosciences include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Kindred Biosciences important for investors?

The ROA of Kindred Biosciences is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Kindred Biosciences take to improve ROA?

To improve ROA, Kindred Biosciences can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Kindred Biosciences pay?

Over the past 12 months, Kindred Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kindred Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kindred Biosciences?

The current dividend yield of Kindred Biosciences is .

When does Kindred Biosciences pay dividends?

Kindred Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kindred Biosciences?

Kindred Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kindred Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kindred Biosciences located?

Kindred Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kindred Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kindred Biosciences from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Kindred Biosciences pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Kindred Biosciences in the year 2023?

In the year 2023, Kindred Biosciences distributed 0 USD as dividends.

In which currency does Kindred Biosciences pay out the dividend?

The dividends of Kindred Biosciences are distributed in USD.